U.S., Aug. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07142057) titled 'An Observational Study on the Impact of the 23-valent Pneumonia Vaccine on Lung Cancer Patients' on Aug. 19.
Brief Summary: To evaluate the impact of the 23-valent pneumonia vaccine on the incidence of pulmonary infection and survival in lung cancer patients, and to explore its preventive effect and safety in the lung cancer patients.
Study Start Date: Sept. 01
Study Type: OBSERVATIONAL
Condition:
LUNG CANCER
Intervention:
BIOLOGICAL: 23-valent pneumococcal vaccine
Receive the 23-valent pneumococcal vaccine; Do not receive the 23-valent pneumococcal vaccine
Recruitment Status: NOT_YET_RECRUITING
Sponsor: The First Affiliate...